Does Rallies show 13F holders for XTLB?

Yes. Rallies tracks hedge fund and 13F ownership data for XTLB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is XTLB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XTLB. It does not provide personalized investment advice.

XTLB (XTL Biopharmaceuticals Ltd. American Depositary Shares) Stock Analysis - Hedge Fund Holdings

XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) is a publicly traded Healthcare sector company. As of May 21, 2026, XTLB trades at $2.52 with a market cap of $6.39M and a P/E ratio of 0.00. XTLB moved -2.57% today. Year to date, XTLB is +1.34%; over the trailing twelve months it is -43.64%. Its 52-week range spans $2.12 to $10.28. Rallies surfaces XTLB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns XTLB stock?

Hedge funds tracked by Rallies that own XTLB include Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for XTL Biopharmaceuticals Ltd. American Depositary Shares.

XTLB Key Metrics

Key financial metrics for XTLB
Metric	Value
Price	$2.52
Market Cap	$6.39M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$10.28
52-Week Low	$2.12
Volume	6
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding XTLB

Citadel Advisors holds 15.44K shares of XTLB, changed +13.23% as of Jun 30, 2024.

Latest XTLB News

XTL Biopharmaceuticals to Issue 40% Equity and Raise $1.5M to Acquire Psyga’s GMP Psilocybin Platform — Apr 29, 2026
XTL Biopharmaceuticals to Execute One-for-Four ADS Reverse Split on March 25, 2026 — Mar 20, 2026

Recent XTLB Insider Trades

EDELMAN JOSEPH sold 9.60M (~$1.47M) on Nov 19, 2008.
EDELMAN JOSEPH sold 24.68M (~$3.48M) on Nov 18, 2008.
EDELMAN JOSEPH sold 2.70M (~$412.02K) on Nov 18, 2008.

XTLB Analyst Consensus

XTLB analyst coverage data. Average price target: $0.00.

Common questions about XTLB

Who owns XTLB stock?: Hedge funds tracked by Rallies that own XTLB include Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for XTL Biopharmaceuticals Ltd. American Depositary Shares.
Does Rallies show 13F holders for XTLB?: Yes. Rallies tracks hedge fund and 13F ownership data for XTLB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is XTLB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XTLB. It does not provide personalized investment advice.